Novartis CEO’s five-year vision for translational science

New modalities, and their next-gen successors are here to stay, but the path to making them mainstream may be longer than is often perceived, according to Novartis CEO Vasant Narasimhan. 

In an interview with BioCentury, Narasimhan expanded on how he sees the next five years unfolding for drug development in new modalities, the challenges he sees in creating a learning healthcare system, and steps that could make pandemic preparedness momentum not fall away as it has in the past. His comments on public policy issues including drug pricing were published last week...